Molecular Formula | C21H19ClFNO4S
|
Molar Mass | 435.9 |
Density | 1.48 |
Melting Point | 175∶C |
Boling Point | 710.0±60.0 °C(Predicted) |
Flash Point | 383.203 °C |
Solubility | DMSO |
pKa | 4.54±0.10(Predicted) |
Storage Condition | Sealed in dry,Store in freezer, under -20°C |
Use | Laropiprant(MK 0524) is a highly active DP1 receptor antagonist, Ki is 0.57 nM, and Ki to DP2 receptor is 750nM. |
In vitro study | Laropiprant is a potent, selective DP receptor antagonist with K i values of 0.57 nM and 2.95 nM for DP receptor and TP Receptor, respectively.. Laropiprant (1 µM) causes a significant inhibition of the aggregation but still counteractes the pronounced inhibition caused by PGD2 (30 nM) and BW245c (3 nM). Laropiprant blocks DP receptor-dependent increase in VASP phosphorylation, as well as inhibition of P-selectin expression, GPIIb/IIIa activation and in vitro thrombus formation. Laropiprant antagonizes the increased platelet aggregation by TP and EP3 receptor activation. Laropiprant (10 µM) and niacin inhibit in vitro thrombus formation. |